A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Phase of Trial: Phase IV
Latest Information Update: 05 Jan 2018
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms UPWARD
- Sponsors Astellas Pharma
- 03 May 2017 Planned End Date changed from 1 Oct 2016 to 30 Jun 2018.
- 18 Feb 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 2017 Genitourinary Cancers Symposium.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium